Skip to main content
. 2016 Jan 26;8(3):237–243. doi: 10.14740/jocmr2467w

Table 2. SGLT2 Inhibitors Prescribed to the Subjects Studied at Baseline (n = 50).

Dapagliflozin 5 mg 16 (32%)
Ipragliflozin 25 mg 4 (8%)
Ipragliflozin 50 mg 10 (20%)
Tofogliflozin 20 mg 7 (14%)
Luseogliflozin 2.5 mg 11 (22%)
Canagliflozin 100 mg 1 (2%)
Empagliflozin 10 mg 1 (2%)